ÜÇ OLGU İLE SENTETİK KANNABİNOİDLER VE KLİNİĞE YANSIMALARI: BİR GÖZDEN GEÇİRME

Merih Altıntaş; Leman İnanç; Hüseyin Güleç

ÜÇ OLGU İLE SENTETİK KANNABİNOİDLER VE KLİNİĞE YANSIMALARI: BİR GÖZDEN GEÇİRME

Yazarlar

Merih Altıntaş Erenköy Ruh ve Sinir Hastalıkları Eğitim ve Araştırma Hastanesi AMATEM Kliniği
Leman İnanç Tokat Dr. Cevdet Aykan Ruh Sağlığı ve Hastalıkları Hastanesi
Hüseyin Güleç Erenköy Ruh ve Sinir Hastalıkları Eğitim ve Araştırma Hastanesi Psikiyatri Kliniği

Anahtar Kelimeler:

Bonzai- Jamaika- Sentetik kannabinoid

Özet

Sentetik kannabinoidler günümüzde toplum sağlığını ve güvenliğini bozan önemli bir problem haline gelmiştir. Bu maddelerin özellikle gençler arasındaki kullanımı tüm dünyada olduğu gibi son yıllarda ülkemizde de artış göstermiştir. Sentetik esrar türevlerinin birçok isimleri olmakla beraber Türkiye’de “Bonzai” ve “Jamaika” isimleri yaygın olarak kullanılmaktadır. Bu maddelerin oldukça ucuz ve kolay ulaşılabilir olmaları yaygınlaşmasına sebep olmaktadır. Sentetik kannabinoidlerin farmakolojik for-mülasyonu maddeyi tasarlayan kişiler tarafından sürekli değiştirildiği için rutin madde tarama testlerinde saptanamamaktadır. Heterojen yapıları ortaya çıkabilecek klinik tablolar hakkında öngörüde bulunmayı zorlaştırmaktadır. Birçok sistemi etkileyebilen ve hayatı tehdit edebilecek tablolara yol açabilen bu maddelerin klinik görünümleri oldukça değişkendir. Sentetik kanna-binoid kullanımı sonrası kişiler yaşadıkları fiziksel ve psikiyatrik belirtiler nedeniyle sıklıkla acil servislere, psikiyatri polikliniklerine ve aile hekimlerine başvurmaktadır. Bu durum birçok sağlık çalışanı için endişe verici hale gelmiştir. Bu maddelerin neden olduğu klinik tabloları tanıma, müdahale ve tedavi konusunda multidisipliner bir yaklaşım gerekmektedir. Bu yazıda sentetik kan-nabinoid kullanan üç olgu sunulmuş ve bu maddelerin neden olabileceği farklı klinik durumlarla ilgili dizin gözden geçirilmiştir.

Kaynaklar

Bozkurt M. Sentetik kannabinoidler: Artık herkesin sorunu. Psikiyatride Güncel 4: 165-177.

Akgül A, Aşçıoğlu F. Uyuşturucu maddelerdeyeni trendler ve erken uyarı sistemi. Demir OÖ, Sever M, (Editörler). Örgütlü Suçlar ve Yeni Trendler. Ankara: Polis Akademisi Yayınları, 2011: 29-56.

Seely KA, Lapoint J, Moran JH, Fattore L. Spice drugs are more than harmless herbal blends: A review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neoropsychop-harmacol Biol Psychiatry 2012; 39: 234-243.

Vardakou I, Pistos C, Spiliopoulou Ch. Spice drugs as a new trend: Mode of action, identification and legislation. Toxicol Lett 2010; 197: 157-162.

Lisi DM. Designer drugs. Patients may be using synthetic cannabinoids more than you think. JEMS 2014; 39: 56-59.

Caviness CM, Tzilos G, Anderson BJ, Stein MD. Synthetic cannabinoids: Use and predictors in a community sample of young adults. Subst Abus 2015; 36: 368-373.

Kalyoncu ÖA, Ünlü B, Taştan U. Gençlerin tehlikeli oyunu: Sentetik kannabinoidler (Bonzai) üzerine bir gözden geçirme. Bağımlılık Dergisi 2014; 15: 150-155.

Cohen J, Morrison S, Greenberg J, Sai-dinejad M. Clinical presentation of intoxication due to synthetic cannabinoids. Pediatrics 2012; 129: 1064-1067.

Pants S, Deshmukh A, Dholaria B, et al. Spicy seizure. Am J Med Sci 2012; 344: 67-68.

Buser GL, Gerona RR, Horowitz BZ, et al. Acute kidney injury associated with smoking synthetic cannabinoid. Clin Toxicol(Phila) 2014; 52: 664-673.

Brewer TL, Collins M. A review of clinical manifestations in adolescent and young adults after use of synthetic cannabinoids. J Spec Pediatr Nurs 2014; 19: 119-126.

Forrester MB. Adolescent synthetic cannabinoid exposures reported to Texas poison center. Pediatr Emerg Care 2012; 28: 985-989.

Heath TS, Burroughs Z, Thomson AJ, Teck-lenburg FW. Acute intoxication caused by synthetic cannabinoid in two adolescents. J Ped Pharmacol Ther 2012; 17: 177-181.

Nelson ME, Bryant SM, Aks SE. Emerging drugs of abuse. Emerg Med Clin North Am 2014; 32: 1-28.

Hermanns-Clausen M, Kneisel S, Szabo B, Auwart-er V. Acute toxicity due to the confirmed consumption of synthetic cannabinoids: Clinical and laboratory findings. Addiction 2013; 108: 534-544.

Bozkurt M, Umut G, Evren C, Karabulut V. Sentetik kannabinoid kullanımı nedeniyle polikliniğe başvuran hastaların klinik özellikleri ve labo-ratuvar sonuçları. Düşünen Adam: Psikiyatri ve Nörolojik Bilimler Dergisi 2014; 27: 328-334.

Harris CR, Brown A. Synthetic cannabinoid intoxication: A case series and review. J Emerg Med 2013; 44: 360-366.

Evren C, Bozkurt M. Sentetik Kannabinoidler: Son Yılların Krizi. Düşünen Adam: Psikiyatri ve Nörolojik Bilimler Dergisi 2013; 26: 1-11.

Brents LK, Prather PL. The K2/Spice Phenomenon: Emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products. Drug Metab Rev 2014; 46: 72-85.

Winstock AR, Barrat MJ. The 12-month prevalence and nature of adverse experiences resulting in emergency medical presentations associated with the use of synthetic cannabinoid products. Hum Psychopharmacol 2013; 28: 390-393.

Khullar V, Jain A, Sattari M. Emergence of new classes of recreatinal drugs-syn-thetic cannabinoids and cathinones. J Gen Intern Med 2014; 29: 1200-1204.

Suarez-Pinilla P, Lopez-Gil J, Crespo-Facor-ro B. Immune system: A possible nexus between cannabinoids and psychosis. Brain Behav Immun. 2014; 40: 269-282.

Fantegrossi WE, Moran JH, Radominska-Pan-dya A, Prather PL. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to delta (9)-THC: Mechanism underlying greater toxicity? Life Sci 2014; 97: 45-54.

Drenzek C, Geller RJ, Steck A, et al. Notes from the field: Severe illness associated with synthetic cannabinoid use-Brunswick Georgia. Morbidity and mortality weekly report 2013; 62; 939.

Auwarter V, Dressen S, Weismann W, etal. Spice and other herbal blends: Harmless incense or cannabinoid designer drugs? Mass Spectrom 2009: 44: 832-37.

Durand D, Delgato LL, de la Parra Pellot DM, Nichols-Vinueza D. Psychosis and severe rhabdomyolysis associated with synthetic cannabinoid use. Clin Schizophr Relat Psychoses 2013; 21: 1-13.

Tanei T, Morita Y, Yashima A, et al. Severe rhabdomyolysis and intracranial hemorrhage associated with synthetic cannabinoid: A case report. No Shinkei Geka 2014; 42: 867-871.

Bhanushali GK, Jain G, Fatima H, et al. AKI associated with synthetic cannabinoids: A case series. Clin J Am Soc Nephrol 2013; 8: 523-526.

Luciano RL, Perazella MA. Nephrotoxic effects of designer drugs: Synthetic is not better. Nat Rev Nephrol 2014; 10: 314-324.

Thornton SL, Wood C, Friesen MW, Gerona RR. Synthetic cannabinoid use associated with acute kidney injury. ClinToxicol(Phila)2013;51:189-190.

Acute kidney injury associated with synthetic cannabinoid use-multiple states, 2012. MMWR Morb Mortal Wkly Rep 2013; 15: 93-98.

Pendergraft WF, Herlitz LC, Thornley-Brown D, et al. Nephrotoxic effects of common and emerging drugs of abuse. Clin J Am Soc Nephrol 2014; 9: 1996-2005.

Tofighi B, Lee JD. Internet highs-seizures after consumption of synthetic cannabinoids purchased online. J Addict Med. 2010; 6: 240-241.

de Havenon A, Chin B, Thomas KC, Afra P. The secret “spice”: An undetectable toxic cause of seizure. Neurohospitalist 2011; 1: 182-186.

Harris CR, Brown A. Synthetic cannabinoid intoxication: A case series and review. J Emerg Med 2013; 44: 360-366.

Lapoint J, James LP, Moran CL, et al. Severe toxicity following synthetic cannabinoid ingestion. Clin Toxicol 2011; 49: 760-764.

Ayhan H, Aslan AN, Süygün H, Durmaz T. Bonsai induced acute myocardial infarction. Turk Kardiyol Dern Ars 2014; 42: 560-563.

Tse R, Kodur S, Squires B, Collins N. Sudden cardiac death complicating acute myocardial infarction following synthetic cannabinoid use. Intern Med J 2014; 44: 934-936.

McKeever RG, Vearrier D, Jacops D, et al. K2-Not the spice of life; Synthetic cannabinoids and ST elevation myocardial infarction: A case report. J Med Toxicol 2015; 11: 129-131.

İbrahim S, Al-Saffar F, Wannenburg T. A unique case of cardiac arrest following K2 abuse. Case Rep Cardiol 2014; 2014: 1-3.

Young AC, Schwarz E, Medina G, et al. Cardiotoxicity associated with the synthetic cannabinoid, K9, with laboratory confirmation. Am J Emerg Med 2012; 30: 1320.e5-7.

Hoyte CO, Jacob J, Monte AA, et al. A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010. Ann Emerg Med 2012: 60: 435-438.

Freeman MJ, Rose DZ, Myers MA, et al. Ischemic stroke after use of the synthetic marijuana “spice”. Neurology 2013; 10: 2090-2093.

Bernson-Leung ME, Leung LY, Kumar S. Synthetic cannabis and acute ischemic stroke. J Stroke Cerebrovasc Disc 2014; 23: 1239-1241.

Takematsu M, Hoffman RS, Nelson LS, et al. A case of acute cerebral ischemia following inhalation of a synthetic cannabinoid. Clin Toxicol(Phila) 2014; 52: 973-975.

Jinwala FN, Gupta M. Synthetic cannabis and respiratory depression. J Child Ado-lesc Psychopharmacol 2012; 22: 459-462.

Fattore L, Fratta W. Beyond THC: The new generation of cannabinoid designer drugs. Front Behav Neurosci 2011; 5: 60-66.

Thomas S, Bliss S, Malik M. Suicidal ideation and self harm following K2 use. J Okla State Med Assoc.2012; 105: 430-433.

Eminler AT, Yıldırım M, Uslan MI, ve ark. Sentetik kannabinoidler (bonzai) ve gastrointestinal sistem üzerine etkileri: Kannabinoid hiperemezis sendromu. Güncel Gastroenteroloji 2014; 18: 461-463.

Sarıkaya M, Taşer N. Bonzai kullanımına bağlı toksik hepatit. EP-17.5. Hepatolo-ji Okulu 30 Mayıs-1 Haziran 2014, Kocaeli.

Öztürk E, Oral A, Özdemir M, Bambul N. Synthetic marijuana “K2” induced ITP. Platelets 2015; 26: 258-259.

Radhakrishnan R, Wilkinson ST, D’Souza DC. Gone to pot- a review of the association between cannabis and psychosis. Frontiers in Psychiatry 2014; 5: 1-24.

Castellanos D, Thorton G. Synthetic cannabinoid use: Recognition and management. J Psychiatr Pract 2012; 18: 86-93.

Celofiga A, Koprivsek J, Klavz J. Use of synthetic cannabinoids in patients with psychotic disorders: Case series. J Dual Diag 2014; 10: 168-173.

Papanti D, Schifano F, Botteon G, et al. “Spiceo-phrenia”: A systematic overview of “spice”-re-lated psychopathological issues and a case report. Hum Psychopharmacol 2013; 28: 379-389.

Every-Palmer S. Synthetic cannabinoid JWH-018 and psychosis: An explorative study. Drug Alcohol Depend. 2011; 117: 152-157.

Müller H, Sperling W, Köhrmann M, et al. The synthetic cannabinoid Spice as a trigger for an acute exacerbation of cannabis induced recurrent psychotic episodes. Schizophr Res 2010; 118: 309-310.

Peglow S, Buchner J, Briscoe G. Synthetic cannabinoid induced psychosis in a previously nonpsychotic patient. Am J Addict 2012; 21: 287-288.

Hurst D, Loeffler G, McLoy R. Psychosis associated with synthetic cannabinoid agonists: A case series. Am J Psychiatry 2011; 168: 1119.

Glue P, Al-Shaqsi, Hancock D, et al. Hospitalisation associated with use of the synthetic cannabinoid K2. N Z Med J 2013, 126: 18-23.

Rech MA, Donahey E, Cappiello Dzied-zic JM, et al. New Drugs of abuse. Pharmacotherapy 2015; 35: 189-197.

ÜÇ OLGU İLE SENTETİK KANNABİNOİDLER VE KLİNİĞE YANSIMALARI: BİR GÖZDEN GEÇİRME